🔎 Trials Near Me

Home › Insomnia › NCT07428629

Piloting an Insomnia Treatment in Patients With Ulcerative Colitis

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Active UC based on PRUCSI
* Insomnia Severity Index score \> 8 and SOL or WASO \> 30 minutes
* Stability of sleep \& UC meds for \> 3 months
* Access to internet or cell phone service sufficient for telehealth

Exclusion Criteria:

* PHQ-9 depression score \> 15
* GAD-7 anxiety score \> 15
* Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)
* Current alcohol or substance abuse
* Current opioid use for pain control
* Current systemic corticosteroid use
* Current pregnancy or nursing
* Ileostomy or colostomy
* Diagnosis of seizure disorder
* Diagnosis of sleep apnea
* Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen
* Night shift, rotating shift work, or frequent travel outside of time zone
* Residence in a state where we cannot conduct telehealth visits

About the study

The goal of this clinical trial is to learn if telehealth-based Cognitive Behavioral Therapy for Insomnia (CBT-I) adapted for Ulcerative Colitis (UC) works to treat insomnia in adults with UC. The main questions it aims to answer are:

* Is telehealth-based CBT-I adapted for UC feasible and acceptable to participants? * Does CBT-I for UC impact insomnia severity and sleep continuity?

Participants will:

* Answer questionnaires online before and after treatment * Complete an online daily sleep diary before, during, and after treatment * Participate in 5 telehealth treatment visits over 7-8 weeks * Participate in 5-10-minute phone calls between treatment visits

What is being tested

Sponsor: Dartmouth-Hitchcock Medical Center · Participants: 20 · Started: Apr 17, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07428629

Locations in the U.S.

New HampshireDartmouth-Hitchcock Medical Center, Lebanon

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.